Victoza

(Liraglutide)

ApprovedPeptide

Liraglutide is used to help people with type 2 diabetes control their blood sugar levels, and it's also used to help with weight loss in people who are overweight or obese.[2] Victoza is currently approved and in use across 48 indications[4].[1]

Victoza is one of 831 small molecule programs targeting Insulin resistance. It is currently in Approved.

Indications

373

Total Trials

Active Trials

830

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

Insulin ResistanceCompleted

Coronary Artery DiseaseActive, not recruiting

Metabolic SyndromeRecruiting

Ischemic CardiomyopathyActive, not recruiting

Transient Ischemic AttackActive, not recruiting

Neuropathic PainActive, not recruiting

Cognitive DisorderTerminated

HypogonadismActive, not recruiting

Coronary StenosisCompleted

Binge EatingCompleted

Insulin ResistanceApproved

Completed

Coronary Artery DiseaseApproved

Active, not recruiting

Metabolic SyndromeApproved

Recruiting

Ischemic CardiomyopathyPreclinical

Active, not recruiting

Transient Ischemic AttackPreclinical

Active, not recruiting

Neuropathic PainPreclinical

Active, not recruiting

Cognitive DisorderApproved

Terminated

HypogonadismApproved

Active, not recruiting

Coronary StenosisApproved

Completed

Binge EatingApproved

Completed

Showing 10 of 47 indications

Competition

Competitive Landscape

176 competitors in Obesity

#DrugCompanyPhaseTrials

Victoza

Novo Nordisk

Approved

19 2

Decadron

AAspen Global Incorporated

Phase 3

2 3

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

1 4

Retatrutide

Eli Lilly

Phase 3

6 5

Berobenatide

Pfizer

Phase 3

5 6

NNC0487-0111

Novo Nordisk

Phase 3

11 7

Naltrexone-Bupropion Combination

CCurrax Pharmaceuticals

Phase 3

2 8

PF-08653944

Pfizer

Phase 3

6 9

Survodutide

Boehringer Ingelheim

Phase 3

2 10

Actemra

Roche

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Post-ApprovalNot yet recruiting

Weight Loss

NCT07301437

Q2 2028

Post-ApprovalRecruiting

Study completion

NCT05681299

Q4 2029

Post-ApprovalRecruiting

Liraglutide

NCT06742710

Clinical

Trials by Indication[1]

Type 2 Diabetes57 trials

A Study of LY3325656 in Healthy Participants and Participants With Type 2 Diabetes

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT03115099·80 enrolled

Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT00331851·584 enrolled

A Long-term Trial to Compare the Effects of Liraglutide and Sulphonylurea (Glimepiride) Both in Combination With Metformin on Clinical, Endothelial and Image Markers of Cardiovascular Risk in Patients With Type 2 Diabetes

Withdrawn·FFundación Fernández-Cruz·Phase 4·NCT01593137

Show 54 more trials

Study of Liraglutide Versus Insulin on Liver Fat Fraction in Patients With Type 2 Diabetes

Completed·—·Phase 2·NCT01399645·35 enrolled

Efficacy and Safety of Liraglutide in Type 2 Diabetes With Lower Extremity Arterial Disease

Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 4·NCT04146155·200 enrolled

Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 4·NCT02730377·1,991 enrolled

Effect of Liraglutide on Weight and Appetite in Obese Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 2·NCT01508949·35 enrolled

Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT01388361·413 enrolled

The Effects of Liraglutide on Sudomotor Function and Inflammation in Type 2 Diabetes

Unknown status·—·Phase 2·NCT03426085·44 enrolled

A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT03235050·834 enrolled

A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

Completed· Novo Nordisk logo

Novo Nordisk·Phase 2·NCT02205528·108 enrolled

Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in Daily Practice

Completed· Novo Nordisk logo

Novo Nordisk··NCT02255266·1,788 enrolled

Safety and Tolerability of Liraglutide in Healthy Volunteers and Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT01507285·24 enrolled

Effects of Lixisenatide Compared to Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes

Completed· Sanofi logo

Sanofi·Phase 2·NCT01175473·148 enrolled

Evaluating the Safety and Effectiveness of Liraglutide in Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk··NCT01403025·4,121 enrolled

Addition of Liraglutide to Patients With Type 2 Diabetes Treated With Multiple Daily Insulin Injections

Completed·VVastra Gotaland Region·Phase 2·NCT02113332·124 enrolled

A Study Using Medical Records of Danish People With Type 2 Diabetes Comparing Empagliflozin and Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) in the Occurrence of Serious Cardiovascular Outcomes

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT03993132·26,774 enrolled

The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study

Completed·UUniversity of Texas Southwestern Medical Center·Phase 4·NCT01966978·157 enrolled

Non-Interventional Study on Safety of Liraglutide in Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk··NCT01345734·1,056 enrolled

GLP-1 and Microvascular Function in Type 2 Diabetes

Completed·RRoyal Devon and Exeter NHS Foundation Trust·N/A·NCT01740921·39 enrolled

The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT00856986·987 enrolled

To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes

Completed· GSK logo

GSK·Phase 2·NCT01725126·53 enrolled

Effect of Liraglutide in Combination With Sulfonylurea (SU) on Blood Glucose Control in Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT00395746·264 enrolled

Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT01620489·279 enrolled

A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004)

Terminated· Merck & Co. logo

Merck & Co.·Phase 2·NCT02492763·176 enrolled

Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT03018028·243 enrolled

A Research Study Looking at How Victoza® Works in People With Type 2 Diabetes in Iran, Followed in Local Clinical Routine

Completed· Novo Nordisk logo

Novo Nordisk··NCT03888157·839 enrolled

A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT03172494·720 enrolled

Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes

Unknown status·TTemple University·Phase 4·NCT02344186·12 enrolled

Effect of Liraglutide on the Beta-cell Responsiveness in Subjects With Type 2 Diabetes Compared to a Healthy Control Group

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT01511185·20 enrolled

The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 4·NCT02008682·368 enrolled

The Impact of Liraglutide on Glucose Tolerance and the Risk of Type 2 Diabetes in Women With Previous Pregnancy-induced Diabetes

Completed·TTina Vilsboll·Phase 4·NCT01795248·105 enrolled

Liraglutide and Heart Failure in Type 2 Diabetes

Completed·TThomas Nystrom·Phase 2·NCT01425580·62 enrolled

Par-4 and Telomere-telomerase System in Type 2 Diabetes Patients Who Received GLP-1 or Metformin Treatment

Unknown status·TThird Military Medical University·Phase 4·NCT02535299·200 enrolled

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT01676116·438 enrolled

Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 2·NCT00154401·177 enrolled

Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT00318422·1,041 enrolled

Title: Therapeutic Targets in African-American Youth With Type 2 Diabetes

Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 1/2·NCT02960659·24 enrolled

A Retrospective Database Assessment of Clinical Effectiveness in Type 2 Diabetes Patients Treated With Liraglutide From Primary Care Centers in Sweden

Completed· Novo Nordisk logo

Novo Nordisk··NCT02077946·1,059 enrolled

Combinatorial Therapy for Peristent Type 2 Diabetes After Gastric Banding

Terminated·—·Phase 4·NCT01597531·1 enrolled

Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT03191396·577 enrolled

Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT00333151·576 enrolled

Observational Study on Efficacy and Safety of Liraglutide in Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk··NCT01226966·3,152 enrolled

Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT00393718·400 enrolled

Effect of Liraglutide on Glucose Profiles and Gastric Emptying in Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 2·NCT01508923·17 enrolled

Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide

Completed·IIntarcia Therapeutics·Phase 3·NCT02638805·136 enrolled

Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes

Completed· Hanmi Pharmaceutical Company Limited logo

Hanmi Pharmaceutical Company Limited·Phase 2·NCT02057172·254 enrolled

Targeting Beta-cell Failure in Lean Patients With Type 2 Diabetes

Completed·UUniversity of Leeds·Phase 4·NCT04657939·57 enrolled

Liraglutide and a Calorie Restricted Diet Augments Weight Loss and Decreases Risk of Type 2 Diabetes and CVD.

Completed·SStanford University·Phase 3·NCT01784965·69 enrolled

Liraglutide and Insulin Therapy in Patients With Type 2 Diabetes

Unknown status·RRadboud University Medical Center·N/A·NCT01392898·50 enrolled

Pharmacodynamic Effects of Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin

Completed· Sanofi logo

Sanofi·Phase 2·NCT01596504·142 enrolled

Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT01336023·1,663 enrolled

Effects of Liraglutide in Young Adults With Type 2 DIAbetes (LYDIA)

Completed·UUniversity of Leicester·Phase 3·NCT02043054·90 enrolled

Effect of Liraglutide on Diastolic Dysfunction on Cardiac MRI in Type 2 Diabetes Patients

Completed·RRigshospitalet, Denmark·Phase 4·NCT02655770·40 enrolled

Study of Liraglutide in Individuals With Type 2 Diabetes Using Insulin

Terminated·UUniversity of Manitoba·Phase 3·NCT01628445·52 enrolled

Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes

Completed·UUniversity of Miami·Phase 4·NCT02014740·100 enrolled

Effect of Liraglutide on Absorption of Paracetamol in Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT01517555·18 enrolled

Liraglutide31 trials

Liraglutide Treatment in Obese Infertile PCOS Women

Recruiting·PPeking University Third Hospital·Phase 4·NCT06742710·890 enrolled

Safety, Tolerability and Pharmacokinetics of Liraglutide-depot in Healthy Subjects

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT01473953·31 enrolled

Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects

Completed·SSun Yat-sen University·Phase 4·NCT02147925·75 enrolled

Show 28 more trials

Effects of Glucagon Like Peptide-1(GLP-1) and Liraglutide on Brain Satiety and Reward Circuits and Feeding Behavior in Diabetes

Completed·AAmsterdam UMC, location VUmc·N/A·NCT01363609·50 enrolled

Evaluation of Liraglutide 3.0mg in Patients With Poor Weight-loss and a Suboptimal Glucagon-like Peptide-1 Response

Completed·UUniversity College, London·Phase 4·NCT03341429·70 enrolled

Impact of Liraglutide 3.0 on Body Fat Distribution

Completed·UUniversity of Texas Southwestern Medical Center·Phase 4·NCT03038620·235 enrolled

Liraglutide on Decreasing Parenteral Support in Short Bowel Patients (SLIPS)

Withdrawn·IImperial College London·Phase 2·NCT03371862

The Effect of Liraglutide on Pancreatic Hormones and Its Size

Completed·NNicolai Jacob Wewer Albrechtsen·N/A·NCT03520062·14 enrolled

Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS

Completed·WWoman's·Phase 3·NCT03480022·88 enrolled

Liraglutide Hospital Discharge Trial

Completed·EEmory University·Phase 4·NCT01919489·273 enrolled

Liraglutide Effects on Epicardial Fat Inflammatory Genes

Completed·UUniversity of Miami·Phase 4·NCT03260881·38 enrolled

Efficacy of Liraglutide Therapy in Patients With IPAA

Terminated·UUniversity of North Carolina, Chapel Hill·Phase 2·NCT04763564·8 enrolled

The Influence of Liraglutide on the Reward Properties of Food: an fMRI Study on Healthy Volunteers

Completed·MMedical University of Vienna·Phase 4·NCT01695109·16 enrolled

The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 2·NCT00422058·564 enrolled

Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure

Completed· Sanofi logo

Sanofi·Phase 4·NCT01117350·978 enrolled

Liraglutide to Improve corONary Haemodynamics During Exercise streSS

Completed·KKing's College London·Phase 2·NCT02315001·26 enrolled

The Effect of Liraglutide Treatment on Postprandial Chylomicron and VLDL Kinetics, Liver Fat and de Novo Lipogenesis

Completed·HHelsinki University Central Hospital·Phase 4·NCT02765399·23 enrolled

Safety and Tolerability of Liraglutide in Subjects With Impaired Kidney Function and in Subjects With Normal Kidney Function

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT01508806·30 enrolled

Effect of Liraglutide Combined With Short-term CSII on Long-term Glycemic Remission and β Cell Function

Unknown status·SSun Yat-sen University·Phase 4·NCT01790308·100 enrolled

Safety and Tolerability of Insulin Degludec/Liraglutide (A3) in Healthy Subjects

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT01319240·24 enrolled

Adding Liraglutide to High Dose Insulin: Breaking the Cycle

Completed·IIldiko Lingvay·Phase 4·NCT01505673·71 enrolled

Effect of Liraglutide on Heart Frequency in Healthy Volunteers

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT01516255·64 enrolled

Safety of Liraglutide in Subjects With Liver Impairment and in Subjects With Normal Liver Function

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT01507389·24 enrolled

Comparison of Three Liraglutide Formulations in Healthy Volunteers

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT01514487·24 enrolled

A Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Obese Children Aged 7 to 11 Years

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT02696148·24 enrolled

Investigating the Effect of Liraglutide on the Endogenous Glucose Production During in Tye 1 Diabetes Subjects

Completed·MMedical University of Graz·Phase 2·NCT02408705·14 enrolled

Safety and Tolerability of Liraglutide in Healthy Japanese Male Volunteers

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT01515592·24 enrolled

A Trial to Assess the Effect of Liraglutide on Blood Triglyceride (Fat) Levels After a Meal in Type 2 Diabetics

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT00993304·20 enrolled

Investigating Bioequivalence Between Single-dose Liraglutide Administered Subcutaneously With Two Different Pen-injectors

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT02207348·24 enrolled

Comparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT01296412·653 enrolled

Identifying Potential Effects of Liraglutide on Degenerative Changes

Completed·UUniversity of Aarhus·N/A·NCT01469351·34 enrolled

Type 2 Diabetes Mellitus13 trials

A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)

Terminated· Eli Lilly logo

Eli Lilly·Phase 4·NCT02072096·192 enrolled

Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus

Unknown status·RRenJi Hospital·N/A·NCT05779644·300 enrolled

A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT01558271·492 enrolled

Show 10 more trials

A Study to Investigate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT03555994·51 enrolled

The Effect of Liraglutide on Left Ventricular Function in Chronic Heart Failure Patients With and Without Type 2 Diabetes Mellitus

Completed·FFlyvbjerg, Allan, DMSc·N/A·NCT01472640·240 enrolled

The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT00700817·665 enrolled

A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus

Completed· Sanofi logo

Sanofi·Phase 2·NCT02973321·296 enrolled

Study of the Safety and Efficacy of MK-8521 Compared to Placebo and a Diabetes Drug in Participants With Type 2 Diabetes Mellitus (MK-8521-003)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT01982630·87 enrolled

Investigating the Safety Profile of Liraglutide Under Normal Conditions of Use in Korean Subjects With Type 2 Diabetes Mellitus

Completed· Novo Nordisk logo

Novo Nordisk··NCT01821846·64 enrolled

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus.

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT02607306·819 enrolled

A Post Marketing Surveillance (PMS) Study of Liraglutide in Subjects With Type 2 Diabetes Mellitus in India

Completed· Novo Nordisk logo

Novo Nordisk··NCT01212133·1,386 enrolled

Liraglutide Improve Cognitive Function in Patients With Type 2 Diabetes Mellitus

Completed·TThird Military Medical University·Phase 3·NCT05360147·30 enrolled

Study to Assess the Efficacy of Liraglutide in Patients With Type 2 Diabetes Mellitus

Completed·—·Phase 3·NCT02889510·76 enrolled

Weight loss9 trials

Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues

Recruiting·UUniversity of Chicago·Phase 1·NCT06171152·30 enrolled

RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients.

Not yet recruiting·TThe Fourth Affiliated Hospital of Zhejiang University School of Medicine·Phase 4·NCT07301437·120 enrolled

Pilot Study of the Effect of Liraglutide 3.0 mg on Weight Loss and Gastric Functions in Obesity

Completed·MMichael Camilleri, MD·Phase 2·NCT03523273·136 enrolled

Show 6 more trials

Weight Loss With Intensive Lifestyle Modifications Plus Bariatric Surgery Versus Liraglutide 3 mg

Completed·—·N/A·NCT03534310·75 enrolled

Effect of Liraglutide on Weight Loss in Patients Who Have Undergone Revisional Bariatric Surgeries.

Unknown status·GGeneral Committee of Teaching Hospitals and Institutes, Egypt·N/A·NCT05285397·60 enrolled

Outcome of Overweight AF Patients Following Ablation With a Potential Weight Loss Medication ( GOAL-AF )

Active, not recruiting·UUniversity Hospital Birmingham··NCT05221229·29 enrolled

Short Term Weight Loss With Liraglutide and Metformin in Infertile Obese PCOS Patients

Completed·UUniversity Medical Centre Ljubljana·Phase 4·NCT03034941·35 enrolled

Pilot Study of the Effect of Liraglutide on Weight Loss and Gastric Functions in Obesity

Completed·MMayo Clinic·Phase 2·NCT02647944·40 enrolled

Combined Effects of GLP-1 Analogue and Exercise on Maintenance of Weight Loss and Health After Very-low Calorie Diet

Unknown status·SSigne Torekov·Phase 4·NCT04122716·215 enrolled

Type 1 Diabetes8 trials

Liraglutide in Newly Onset Type 1 Diabetes.

Completed·HHvidovre University Hospital·Phase 2/3·NCT01879917·65 enrolled

The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT01836523·1,398 enrolled

The Effect of Liraglutide Adjunct to Insulin on Glucagon Response to Hypoglycaemia in Subjects With Type 1 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT01536665·45 enrolled

Show 5 more trials

Liraglutide as add-on to Insulin in Type 1 Diabetes

Completed·HHvidovre University Hospital·Phase 3·NCT02092896·40 enrolled

Liraglutide In Overweight Patients With Type 1 Diabetes

Completed·UUniversity at Buffalo·Phase 3·NCT01753362·84 enrolled

Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes

Completed·UUniversity at Buffalo·Phase 3·NCT02518945·26 enrolled

Liraglutide in Type 1 Diabetes

Completed·SSteno Diabetes Center Copenhagen·Phase 4·NCT01612468·100 enrolled

Liraglutide in Adolescents With Type 1 Diabetes

Completed·UUniversity at Buffalo·Phase 3·NCT02516657·5 enrolled

55 more indications

Obesity7 trials

Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT02918279·251 enrolled

Obesity Treatment to Improve Diabetes

Completed·DDasman Diabetes Institute·N/A·NCT05390307·60 enrolled

Effect of Liraglutide on Microbiome in Obesity

Unknown status·FFederico II University·Phase 4·NCT04046822·70 enrolled

Show 4 more trials

Study of the Cardiometabolic Effects of Obesity Pharmacotherapy

Unknown status·NNational and Kapodistrian University of Athens·Phase 4·NCT04575194·40 enrolled

A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America

Completed· Novo Nordisk logo

Novo Nordisk·Phase 4·NCT05579249·500 enrolled

Anti-obesity Pharmacotherapy and Inflammation

Active, not recruiting·LLouisiana State University Health Sciences Center in New Orleans··NCT05756764·30 enrolled

Liraglutide (Saxenda(R)) in Adolescents With Obesity After Sleeve Gastrectomy

Completed·EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·Phase 2·NCT04883346·34 enrolled

Overweight4 trials

A Regulatory Post-marketing Surveillance (rPMS) Study to Evaluate the Safety and Effectiveness of Saxenda®(Liraglutide 3.0 mg) in Obese Patients and Overweight Patients With Obesity-related Comorbidities in Routine Clinical Practice in Korea.

Completed· Novo Nordisk logo

Novo Nordisk··NCT03560336·758 enrolled

A Study of Tirzepatide in Overweight and Very Overweight Participants

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT04311411·114 enrolled

Efficacy and Safety of Liraglutide on Body Weight in Obese Subjects or Overweight Subjects With Co-morbidities

Unknown status·XXiangya Hospital of Central South University·Phase 3·NCT04487743·300 enrolled

Show 1 more trial

Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT02235961·163 enrolled

Diabetes Mellitus4 trials

Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients

Completed·LLeiden University Medical Center·Phase 4·NCT01761318·50 enrolled

Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus

Completed· Novo Nordisk logo

Novo Nordisk·Phase 2·NCT02453711·957 enrolled

Liraglutide or Insulin in Real Life Usage in Patients With Diabetes Mellitus Type 2

Completed· Novo Nordisk logo

Novo Nordisk··NCT01484262·1,344 enrolled

Show 1 more trial

Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients of South Asian Descent

Completed·LLeiden University Medical Center·Phase 4·NCT02660047·51 enrolled

Polycystic Ovary Syndrome3 trials

LIPT - Liraglutide in Polycystic Ovary Syndrome

Completed·JJens Faber·Phase 4·NCT02073929·72 enrolled

Polycystic Ovary Syndrome and Liraglutide as Add-on Therapy on Metformin

Completed·UUniversity Medical Centre Ljubljana·Phase 4·NCT01911468·36 enrolled

PDE-4 Inhibitor Roflumilast and GLP-1 Agonist Liraglutide in Polycystic Ovary Syndrome

Completed·UUniversity Medical Centre Ljubljana·Phase 4·NCT02187250·45 enrolled

Obese Patients3 trials

Laparocopic Sleeve Gastrectomy With or Without Liraglutide in Obese Patients

Completed·PPost Graduate Institute of Medical Education and Research, Chandigarh·Phase 3·NCT04325581·16 enrolled

Effects of Benaglutide on Weight and Gut Microbiota in Obese Patients

Unknown status·XXiangya Hospital of Central South University·Phase 3·NCT03986008·60 enrolled

The Effect and the Pharmacogenomics Study of Liraglutide in Obese Patients

Withdrawn·XXiangya Hospital of Central South University·Phase 2·NCT04839237

Weight Management3 trials

In Market Utilisation of Liraglutide Used for Weight Management in the UK: a Study in the CPRD Primary Care Database

Completed· Novo Nordisk logo

Novo Nordisk··NCT03479762·105 enrolled

Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan.

Completed· Novo Nordisk logo

Novo Nordisk··NCT06283641·300 enrolled

In-market Utilisation of Liraglutide Used for Weight Management in Europe

Completed· Novo Nordisk logo

Novo Nordisk··NCT02967757·316 enrolled

GLP-12 trials

Investigation of the Relationship Between Peripheral and Central Metabolic Changes Induced by GLP-1 Agonists

Completed·NNils Opel·N/A·NCT06818292·10 enrolled

Cooperation of Insulin and GLP-1 on Myocardial Glucose Uptake

Completed·IIndiana University·N/A·NCT01232946·30 enrolled

Diabetes2 trials

Replication of the LEAD-2 Diabetes Trial in Healthcare Claims Data

Completed·—··NCT05162183·3,474 enrolled

Replication of the LEADER Diabetes Trial in Healthcare Claims

Completed·—··NCT03936049·168,690 enrolled

Coronary Artery Disease2 trials

The Effect of Liraglutide on the Treatment of Coronary Artery Disease and Type 2 Diabetes

Completed·HHaugaard, Steen Bendix, M.D., DMSc·Phase 4·NCT01595789·41 enrolled

Effects of Agonists of Glucagon Like Peptide - 1 Receptors (GLP-1R) on Arterial Stiffness, Endothelial Glycocalyx and Coronary Flow Reserve in Patients With Coronary Artery Disease and Patients With Diabetes Mellitus

Completed·UUniversity of Athens·N/A·NCT03010683·60 enrolled

Type 2 Diabetic Patients2 trials

Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients

Completed·TThe University of Texas Health Science Center at San Antonio·N/A·NCT02324842·45 enrolled

Effects of Liraglutide on Kidney Function in Type 2 Diabetic Patients

Completed·UUniversity of Aarhus·Phase 4·NCT01664676·11 enrolled

Hyperglycemia2 trials

Liraglutide Efficacy on Glucocorticoid Induced Hyperglycemia in Patients High Risk for Diabetes

Unknown status·RRabin Medical Center·Phase 3·NCT02016846·36 enrolled

Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly

Completed· Novartis logo

Novartis·Phase 4·NCT02060383·249 enrolled

Psoriasis2 trials

GLP-1 Receptors in Normal Skin and Skin From Patients With Psoriasis

Unknown status·UUniversity Hospital, Gentofte, Copenhagen·N/A·NCT01451905·12 enrolled

The Effect of Glucagon Like Peptide (GLP)-1 in Psoriasis

Completed·AAnnesofie Faurschou·N/A·NCT01460069·20 enrolled

Safety and Efficacy1 trial

A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT03486392·474 enrolled

Cardiovascular Disease1 trial

Effect of Liraglutide on the Metabolic Profile in Patients With Type 2 Diabetes and Cardiovascular Disease

Withdrawn·RRWTH Aachen University·Phase 3·NCT04057261

Infertility1 trial

Liraglutide and Metformin Combination on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With PCOS, Obesity and Infertility

Unknown status·MMỹ Đức Hospital·Phase 3·NCT05952882·188 enrolled

Binge Eating1 trial

Binge Eating Liraglutide Intervention

Terminated·KKelly Allison·Phase 3·NCT03279731·36 enrolled

SGLT2 Inhibitors1 trial

LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT02964247·303 enrolled

Obstructive Sleep Apnea1 trial

Effect of Liraglutide vs CPAP on Cardiometabolic Outcomes in Obstructive Sleep Apnea

Completed·SSt Vincent's University Hospital, Ireland·N/A·NCT04186494·30 enrolled

Bile Acid Malabsorption1 trial

Treatment of Bile Acid Malabsorption With Liraglutide

Completed·FFilip Krag Knop·Phase 4·NCT03955575·52 enrolled

Diabetic Neuropathy1 trial

Treatment of Diabetic Neuropathy With Liraglutide

Completed·—·N/A·NCT02138045·39 enrolled

Opioid Use Disorder1 trial

Use of a GLP-1R Agonist to Treat Opioid Use Disorder

Completed·MMilton S. Hershey Medical Center·Phase 1/2·NCT04199728·27 enrolled

Efficacy and Safety1 trial

Comparing Efficacy and Safety of CinnaGen-liraglutide Versus Victoza® in Patients With Type II Diabetes

Unknown status·CCinnagen·Phase 3·NCT03421119·300 enrolled

Bariatric Surgery1 trial

Liraglutide for Low-responders After Bariatric Surgery

Withdrawn·ZZuyderland Medisch Centrum·N/A·NCT04643301

Ischemic Cardiomyopathy1 trial

Clinical Study of Liraglutide in Improving Cardiac Function for Patients With Ischemic Cardiomyopathy

Unknown status·—·N/A·NCT02930265·400 enrolled

Alzheimer's Disease1 trial

Evaluating Liraglutide in Alzheimer's Disease

Unknown status·IImperial College London·Phase 2·NCT01843075·204 enrolled

Hypogonadism1 trial

Testosterone Replacement Therapy and Liraglutide Effects on Weight Loss in Hypogonadism.

Completed·UUniversity Medical Centre Ljubljana·Phase 4·NCT03619330·30 enrolled

Psoriatic Arthritis1 trial

Psoriatic Arthritis Treated With Liraglutide Therapy: a QUality of Life and Efficacy Study

Withdrawn·UUniversity Health Network, Toronto·Phase 2·NCT02472717

Type 1 Diabetes Mellitus1 trial

Liraglutide in the Treatment of Type 1 Diabetes Mellitus

Completed·UUniversity at Buffalo·Phase 3·NCT01722266·72 enrolled

Renal insufficiency1 trial

Liraglutide Treatment to Patients With Severe Renal Insufficiency

Completed·BBo Feldt-Rasmussen·Phase 4·NCT01394341·40 enrolled

Vascular Inflammation1 trial

Effect of Liraglutide on Vascular Inflammation in Type-2 Diabetes

Completed·SSteno Diabetes Center Copenhagen·Phase 4·NCT03449654·102 enrolled

Trial1 trial

The Lira Pump Trial

Completed·HHvidovre University Hospital·Phase 2/3·NCT02351232·44 enrolled

Bipolar Disorder1 trial

Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated)

Completed·LLindner Center of HOPE·Phase 2·NCT03158805·60 enrolled

Concentration1 trial

To Investigate the Blood Concentration of Liraglutide as Well as the Effects on Glucose and Insulin After 21 Days of Daily Subcutaneous Injections of Liraglutide or Placebo

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT00761540·37 enrolled

Tolerance1 trial

Does a GLP-1 Receptor Agonist Change Glucose Tolerance in Antipsychotic-treated Patients?

Unknown status·—·Phase 2·NCT01845259·103 enrolled

Medication1 trial

RISE Adult Medication Study

Completed·RRISE Study Group·Phase 3·NCT01779362·267 enrolled

RCT1 trial

Harmonizing RCT-Duplicate Emulations In A Real World Replication Program (HARRP)

Completed· AstraZeneca logo

AstraZeneca··NCT06099067·239,990 enrolled

Gastrointestinal1 trial

Effect of Liraglutide on Gastrointestinal Absorption of Several Drugs and Potential Influence of Liraglutide on Intragastric pH

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT01518166·70 enrolled

Postmenopausal Women1 trial

Influence on the Effect of an Oral Contraceptive Drug After Administration of Liraglutide in Postmenopausal Women

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT01508858·21 enrolled

Cognitive Dysfunction1 trial

Cognitive Dysfunction and Glucagon-like Peptide-1 Agonists

Completed·UUniversity Health Network, Toronto·Phase 3·NCT02423824·21 enrolled

PreDiabetes1 trial

Improving Beta Cell Function in Mexican American Women With Prediabetes

Completed·OOhio State University·Phase 4·NCT02488057·360 enrolled

Prader-Willi syndrome1 trial

Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT02527200·56 enrolled

Chronic Obstructive Pulmonary Disease1 trial

Effects of Liraglutide in Chronic Obstructive Pulmonary Disease

Completed·CClaus Bogh Juhl·Phase 4·NCT03466021·40 enrolled

Type 1 Diabetic1 trial

GLP-1 Analogue Treatment in Uncontrolled Type 1 Diabetic Patients

Unknown status·HHadassah Medical Organization·Phase 4·NCT01592279·124 enrolled

Effectiveness1 trial

Study of Effectiveness of Liraglutide Added to High Dose Insulin in Type II Diabetics

Completed·MMountain Diabetes and Endocrine Center·Phase 4·NCT01654120·37 enrolled

Maturity-Onset Diabetes of the Young1 trial

The Effects of GLP-1 in Maturity-Onset Diabetes of The Young (MODY)

Completed·UUniversity Hospital, Gentofte, Copenhagen·Phase 2/3·NCT01610934·15 enrolled

Kidney Disease1 trial

The Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Diabetic Kidney Disease

Completed·KKarl Neff·Phase 3·NCT01847313·20 enrolled

ART1 trial

A Study of LY3537021 in Healthy Participants

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT05444569·47 enrolled

Local1 trial

INSPIRE Turkey :A Research Study Looking at the Clinical Parameters Associated With Use and Discontinuation of Saxenda® in Local Clinical Practice in Turkey by Analysing Past Patient Medical Records

Withdrawn· Novo Nordisk logo

Novo Nordisk··NCT05438186

Transient Ischemic Attack1 trial

Liraglutide in Acute Minor Ischemic Stroke or High-risk Transient Ischemic Attack Patients With Type 2 Diabetes Mellitus

Unknown status·FFirst Affiliated Hospital of Jinan University·N/A·NCT03948347·1,708 enrolled

Gastroesophageal Reflux1 trial

Effects of Victoza® Versus Lyxumia® on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion

Terminated·PProfil Institut für Stoffwechselforschung GmbH·Phase 1·NCT02231658·109 enrolled

Heart Failure1 trial

Functional Impact of GLP-1 for Heart Failure Treatment (FIGHT)

Completed·—·Phase 2·NCT01800968·300 enrolled

Parkinson's Disease1 trial

Safety and Efficacy of Liraglutide in Parkinson's Disease

Completed·—·Phase 2·NCT02953665·63 enrolled

Non-Alcoholic Steatohepatitis1 trial

Comparing Effects of Liraglutide and Bariatric Surgery on Weight Loss, Liver Function, Body Composition, Insulin Resistance, Endothelial Function and Biomarkers of Non-alcoholic Steatohepatitis (NASH) in Obese Asian Adults

Unknown status·—·Phase 3·NCT02654665·36 enrolled

Exercise1 trial

GLP-1 and Non-exercise Activity Thermogenesis in RHZ

Terminated·MMaastricht University Medical Center·Phase 4·NCT01638260·22 enrolled

Unspecified4 trials

Effects of GH and Lirglutide on AgRP

Recruiting·—·Phase 4·NCT05681299·40 enrolled

Antidiabetic Effects on Intrahepatic Fat

Completed·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 4·NCT03068065·87 enrolled

Incretin Effect on the Immunological Phenotype

Completed·MMedical University of Graz·Phase 2·NCT01782261·15 enrolled

Show 1 more trial

Effects of Glucagon Like Peptide-1 on No-reflow

Unknown status·—·N/A·NCT02507128·190 enrolled

Regulatory

FDA Approval Timeline[5]

Jan 25, 2010

VICTOZA

NDA NDA022341

Dec 22, 2010

VICTOZA

NDA NDA022341

May 18, 2011

VICTOZA

NDA NDA022341

Apr 6, 2012

VICTOZA

NDA NDA022341

Apr 6, 2012

VICTOZA

NDA NDA022341

Apr 6, 2012

VICTOZA

NDA NDA022341

Dec 3, 2012

VICTOZA

NDA NDA022341

Dec 13, 2012

VICTOZA

NDA NDA022341

Apr 16, 2013

VICTOZA

NDA NDA022341

Jun 13, 2013

VICTOZA

NDA NDA022341

Jul 31, 2014

VICTOZA

NDA NDA022341

Dec 23, 2014

SAXENDA

NDA NDA206321

Feb 25, 2015

VICTOZA

NDA NDA022341

Mar 9, 2015

VICTOZA

NDA NDA022341

Jul 1, 2015

VICTOZA

NDA NDA022341

Apr 22, 2016

VICTOZA

NDA NDA022341

Sep 20, 2016

VICTOZA

NDA NDA022341

Apr 25, 2017

VICTOZA

NDA NDA022341

Jul 26, 2017

VICTOZA

NDA NDA022341

Aug 25, 2017

VICTOZA

NDA NDA022341

Jun 17, 2019

VICTOZA

NDA NDA022341

Aug 5, 2020

VICTOZA

NDA NDA022341

Nov 20, 2020

VICTOZA

NDA NDA022341

Jun 10, 2022

VICTOZA

NDA NDA022341

Jun 10, 2022

VICTOZA

NDA NDA022341

Jul 5, 2023

VICTOZA

NDA NDA022341

Nov 1, 2024

VICTOZA

NDA NDA022341

Feb 12, 2025

VICTOZA

NDA NDA022341

May 28, 2025

VICTOZA

NDA NDA022341

Oct 14, 2025

VICTOZA

NDA NDA022341

Sources

References

[1]
ClinicalTrials.gov — 373 trial records for Liraglutide. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Victoza drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Liraglutide compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Liraglutide. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA022341). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Victoza. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Novo Nordisk company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Glucagon-Like Peptide 1 Receptor Agonist[3]
Modality: Peptide[3]
Highest Phase: Approved[1]
Company: Novo Nordisk

Patent Landscape[6]

Patent Cliff

Jan 9, 2037

Earliest patent expiration — generic entry possible after this date

Patent #Expires

8114833Aug 13, 2025

8114833*PEDFeb 13, 2026

9968659Jan 9, 2037

9968659*PEDJul 9, 2037

Victoza

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q2 2028

Q4 2029

Trials by Indication[1]

Type 2 Diabetes57 trials

Liraglutide31 trials

Type 2 Diabetes Mellitus13 trials

Weight loss9 trials

Type 1 Diabetes8 trials

Obesity7 trials

Overweight4 trials

Diabetes Mellitus4 trials

Polycystic Ovary Syndrome3 trials

Obese Patients3 trials

Weight Management3 trials

GLP-12 trials

Diabetes2 trials

Coronary Artery Disease2 trials

Type 2 Diabetic Patients2 trials

Hyperglycemia2 trials

Psoriasis2 trials

Safety and Efficacy1 trial

Cardiovascular Disease1 trial

Infertility1 trial

Binge Eating1 trial

SGLT2 Inhibitors1 trial

Obstructive Sleep Apnea1 trial

Bile Acid Malabsorption1 trial

Diabetic Neuropathy1 trial

Opioid Use Disorder1 trial

Efficacy and Safety1 trial

Bariatric Surgery1 trial

Ischemic Cardiomyopathy1 trial

Alzheimer's Disease1 trial

Hypogonadism1 trial

Psoriatic Arthritis1 trial

Type 1 Diabetes Mellitus1 trial

Renal insufficiency1 trial

Vascular Inflammation1 trial

Trial1 trial

Bipolar Disorder1 trial

Concentration1 trial

Tolerance1 trial

Medication1 trial

RCT1 trial

Gastrointestinal1 trial

Postmenopausal Women1 trial

Cognitive Dysfunction1 trial

PreDiabetes1 trial

Prader-Willi syndrome1 trial

Chronic Obstructive Pulmonary Disease1 trial

Type 1 Diabetic1 trial

Effectiveness1 trial

Maturity-Onset Diabetes of the Young1 trial

Kidney Disease1 trial

ART1 trial

Local1 trial

Transient Ischemic Attack1 trial

Gastroesophageal Reflux1 trial

Heart Failure1 trial

Parkinson's Disease1 trial

Non-Alcoholic Steatohepatitis1 trial

Exercise1 trial

Unspecified4 trials

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Patent Landscape[6]

Related News